Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.

about

Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.

P2860

Q54243380-118E963C-CDF9-49D3-9A17-5948A2DC1E88

P2860

Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.

Item

http://www.wikidata.org/entity/Q40109740

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Retrospective analysis of goal ...... -switch to tablet formulation.

@en

type

Item

label

Retrospective analysis of goal ...... -switch to tablet formulation.

@en

prefLabel

Retrospective analysis of goal ...... -switch to tablet formulation.

@en

P1476

Retrospective analysis of goal ...... -switch to tablet formulation.

@en

P2093

Kristin M Widmer

http://www.w3.org/2001/XMLSchema#string

Michael J Fallon

http://www.w3.org/2001/XMLSchema#string

Tyler K Liebenstein

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Posaconazole: an oral triazole with an extended spectrum of activity

Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.

Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational s

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

P304

1078155217722405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217722405

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28768441

http://www.w3.org/2001/XMLSchema#string

Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.

about

P2860

P2860

Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698